Inventor · disambiguated record
Lorianne Masuoka
Also filed as: MASUOKA LORIANNE · MASUOKA LORIANNE K
9 granted patents·12 pending applications·120 citations·filing 2001–2024
88Inventor score
Files withMARINUS PHARMACEUTICALS INC8NOVARTIS VACCINES & DIAGNOSTIC6LIN JUNYU3CHIRON CORP1CHU KETING1
Top patents by PatentIndex Score
21 records- 0196US7445780B2Antagonistic anti-CD40 antibodiesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2007·Granted Nov 4, 2008·54 cites·6 claims
- 0292US11110100B2Ganaxolone for use in treatment of status epilepticusMARINUS PHARMACEUTICALS INC·Filed 2021·Granted Sep 7, 2021·3 cites·21 claims
- 0392US7820170B2Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodiesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2009·Granted Oct 26, 2010·18 cites·10 claims
- 0490US7288252B2Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodiesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2001·Granted Oct 30, 2007·32 cites·10 claims
- 0587US12246026B2Ganaxolone for use in treatment of status epilepticusMARINUS PHARMACEUTICALS INC·Filed 2021·Granted Mar 11, 2025·1 cites·26 claims
- 0684US8088383B2Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodiesCHU KETING·Filed 2010·Granted Jan 3, 2012·8 cites·6 claims
- 0783US7611708B2Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodiesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2008·Granted Nov 3, 2009·4 cites·9 claims
- 0880US2023405021A1Ganaxolone for use in treatment of status epilepticusMARINUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0978US11679117B2Ganaxolone for use in treatment of status epilepticusMARINUS PHARMACEUTICALS INC·Filed 2022·Granted Jun 20, 2023·0 cites·28 claims
- 1078US2025082651A1Ganaxolone for use in treating genetic epileptic disordersMARINUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1170US2022249515A1Ganaxolone for use in treating genetic epileptic disordersMARINUS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1265US11266662B2Ganaxolone for use in prophylaxis and treatment of postpartum depressionMARINUS PHARMACEUTICALS INC·Filed 2019·Granted Mar 8, 2022·0 cites·20 claims
- 1364US2019160078A1Ganaxolone for use in treating genetic epileptic disordersMARINUS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1464US2010172869A1Method for treating multiple sclerosisNOVARTIS VACCINES & DIAGNOSTIC·Filed 2009·Application pending·0 cites
- 1558US2008075697A1Methods for treating multiple sclerosisNOVARTIS VACCINES & DIAGNOSTIC·Filed 2007·Application pending·0 cites
- 1650US2003082138A1Methods for treating multiple sclerosisCHIRON CORP·Filed 2002·Application pending·0 cites
- 1747US2007248605A1Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic InterventionFIVE PRIME THERAPETUTICS INC·Filed 2004·Application pending·0 cites
- 1846US2010210829A1Compositions and Methods for Treating Diseases, Disorders, or Conditions Characterized by Myelin Degeneration, Myelin Deficiency or LossFIVE PRIME THERAPEUTICS INC·Filed 2008·Application pending·0 cites
- 1942US2011319324A1Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseasesLIN JUNYU·Filed 2010·Application pending·0 cites
- 2042US2007054851A1Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseasesLIN JUNYU·Filed 2006·Application pending·0 cites
- 2139US2007054852A1Compositions and methods of use of Semaphorin 3F and antagonists thereof in the stimulation of neuromuscular regeneration and treatment of muscular diseasesLIN JUNYU·Filed 2006·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →